New hope for rare kidney disease: experimental drug YOLT-203 enters phase 2 trial
Disease control
Recruiting now
This study tests an experimental drug, YOLT-203, in 36 children and adults with primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes painful kidney stones and kidney damage. The goal is to see if a single dose can safely lower oxalate levels in urine and blood…
Phase: PHASE2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC